Genocea Biosciences Inc (NASDAQ:GNCA)
Genocea Biosciences Inc (NASDAQ:GNCA) gapped higher in Monday’s trading session, after reporting top line Phase 2b clinical trial results for its Genital Herpes candidate drug GEN-003. The stock was up by 15.45% to end the day at $5.83 a share.
Analysts Bullish Bets
Monday’s rally helped reverse a strong downward, but short-term, trend. The stock of Genocea Biosciences Inc (NASDAQ:GNCA) faces resistance at the $6 a share mark as it continues to trade in a tight $5.12-$6.04 trading range. It now awaits to be seen if a wave of bullish coverage from analysts and equity firms will help push the stock higher from current trading levels.
In a research note to investors, Needham analyst, Alan Carr, has upgraded Genocea Biosciences Inc. (NASDAQ:GNCA) shares with a new share price target of $12. The upgrade is based on the company top-line clinical results on its genital herpes candidate drug.
“Our $12 price target is based on 25x our $1.89 2024 EPS est, discounted 25% annually. We assume $750M peak U.S. sales 2030 based on average $750/pt/yr revenue w/ 5% annual price increases. We assume BLA submission mid-2021 and U.S. commercial launch mid-2022,” said Mr. Carr.
Cowen analyst, Phil Nadeau, has also initiated coverage of Genocea Biosciences Inc. (NASDAQ:GNCA) with an ‘outperform’ rating. The analyst has a $40 a share price target. The analyst, in a research note to investors, maintains that GEN-003 stands a higher chance of succeeding in Phase 3 trial which should present a significant commercial opportunity for the company.
GEN-003 Topline results
In the 12-month Phase 2b clinical trial, GEN-003 reduced the median genital lesion rate by 49% compared to a placebo. The candidate drug achieved and improved its clinical endpoints with no changes in its safety profile.
The trial results, according to Genocea Biosciences Inc. (NASDAQ:GNCA) Chief Executive Officer Chip Clark, solidify the strong clinical profile of Gene-003 as a novel treatment for Genital Herpes. Former chair of the Centers for Disease Control, Jonathan Temte, expects the immunotherapy to change the treatment paradigm for patients with the condition.
“The benefits of using a periodic immunization to achieve fewer and shorter genital herpes outbreaks without the compliance challenges of a daily pill burden would represent an extremely important alternative for patients with genital herpes,” said Mr. Temte.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $GNCA and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.